The now-dominant COVID-19 delta variant spreads so quickly that every missed opportunity to catch an infectious person can lead to many more new cases.
For Max Nisen's latest contributions to The Japan Times, see below:
Moderna's COVID-19 windfall sees its market valuation surged by more than $100 billion since May.
A big question is whether New York, another large city that has reopened after having been through the COVID-19 wringer in 2020, will face a similar resurgence of cases like London.
Most of the FDA's decisions don’t receive national attention, which means they may not be rectified until substantial harm is done.
The vaccine is also more stable and easily stored than mRNA vaccines, which will be helpful in broad distribution.
Alongside recent results from Pfizer, the news that a vaccine is proving effective is a great step forward.
Renewed outbreaks highlight the need for a better approach to containing the virus, and broad surveillance testing offers a way forward that's easy on the economy.
Investors watching the COVID-19 vaccine development process could be forgiven for thinking it's not so hard. The effort has moved extraordinarily quickly so far, and with few hiccups. That isn’t how things usually go, especially for new diseases. The world got a reminder Tuesday as ...
The FDA usually wants high standards while drugmakers push boundaries. But political pressure and public unease over a rushed process has forced a role reversal.
Pandemics make for strange bedfellows.